A cross-sectional survey of patient satisfaction and subjective experiences of treatment with fingolimod

BACKGROUND: Fingolimod is the first oral disease-modifying therapy indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical relapses and delay the progression of physical disability caused by MS. OBJECTIVE: To obtain data from MS pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Hanson, Kristin A, Agashivala, Neetu, Stringer, Sonja M, Balantac, Zaneta, Brandes, David W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633540/
https://www.ncbi.nlm.nih.gov/pubmed/23620662
http://dx.doi.org/10.2147/PPA.S41992

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633540/
https://www.ncbi.nlm.nih.gov/pubmed/23620662
http://dx.doi.org/10.2147/PPA.S41992

Ejemplares similares